 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Celltrion announced on the 5th that it has signed a contract with U.S. bio company "Rani Therapeutics" to develop an autoimmune disease treatment called "oral Adalimumab" (development name RT-105).
Celltrion developed CT-P17, a biosimilar (biopharmaceutical generic drug) of Humira, a blockbuster autoimmune disease treatment used for rheumatoid arthritis, spinal arthritis and psoriasis, and received approval from the European Medicines Agency (EMA) and item approval from the U.S. Food and Drug Administration (FDA).
RT-105, which Celltrion signed a development contract this time, has changed its formulation to a drug that takes CT-P17, an injection.
Rani Therapeutics has the technology to change intravenous and subcutaneous protein and antibody drugs for oral use.
Under the contract, Celltrion will exclusively supply CT-P17 necessary for RT-105 development and have priority negotiation rights on global development and sales rights based on the results of phase 1 clinical trials.
Celltrion also signed a contract with Rani Therapeutics in January to develop 'RT-111', which converts the biosimilar CT-P43 of the autoimmune disease treatment 'Stella' into oral form.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
